PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Pucotenlimab

Drugs in development · updated 30 October 2026

Pucotenlimab: clinical trials and development status

Other names and codes: HX008

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Pucotenlimab is in 49 active clinical trials (recruiting or ongoing, phases I–III) for 21 diseases. The most advanced phase is III.

49Active trials
IIIMost advanced phase
21Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pucotenlimab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
CholangiocarcinomaII–III3NCT07598318
Colorectal neoplasmIII3NCT05652894
Nasopharyngeal CarcinomaIII1NCT06976190
Head and neck squamous cell carcinomaII9NCT07844551
Penile neoplasmII4NCT07497919
Head and neck neoplasmsII3NCT07766889
MelanomaII3NCT07750067
CarcinomaII2NCT07844551
Non-small-cell lung carcinomaII2NCT07882940
Rectal neoplasmII2NCT06770270
Stomach neoplasmII2NCT07692334
AdenocarcinomaII1NCT07692334
Biliary tract neoplasmII1NCT07649980
Gastrointestinal neoplasmI–II1NCT03866525
Hepatocellular carcinomaI–II1NCT07479485
Nasopharyngeal neoplasmII1NCT07524413
NeoplasmI–II1NCT06456892
Pancreatic neoplasmI–II1NCT07312422
Renal cell carcinomaII1NCT07386158
RhabdomyosarcomaI–II1NCT06456892
Thyroid neoplasmII1NCT07235566

Everything on Pucotenlimab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch